Royal Bank Plaza
Suite 2800 South Tower 200 Bay Street
Toronto, ON M5J 2J1
Canada
https://satellos.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, President & Director | 591,66k | N/A | 1955 |
Ms. Elizabeth Williams CA, CPA | CFO & Corporate Secretary | 250,19k | N/A | 1978 |
Dr. Philip Lambert M.A., Ph.D. | Chief Scientific Officer | 632,53k | N/A | 1969 |
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Strategic Advisor | 32,53k | N/A | 1960 |
Ms. Desiree Chan | Chief of Staff | N/A | N/A | N/A |
Ms. Courtney Wells | Senior Vice President of Clinical Development Operations | N/A | N/A | N/A |
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Satellos Bioscience Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.